The treatment of ACE inhibitors reduce risk of cardiovascular morbidity and mortality. The patients with grade 1-2 hypertension (n=2060) and at least one additional risk factors, subclinical organ damage, established CV or renal disease, diabetes mellitus or metabolic syndrome are recruited in this clinical study. The article presented of study design.